These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33135826)

  • 1. Certolizumab pegol for hidradenitis suppurativa: Case report and literature review.
    Holm JG; Jørgensen AR; Yao Y; Thomsen SF
    Dermatol Ther; 2020 Nov; 33(6):e14494. PubMed ID: 33135826
    [No Abstract]   [Full Text] [Related]  

  • 2. Certolizumab pegol as an alternative treatment in patients with coexisting hidradenitis suppurativa and other inflammatory immune-mediated diseases: Report of two cases.
    Melgosa Ramos FJ; García Ruiz R; Mateu Puchades A
    Dermatol Ther; 2022 May; 35(5):e15401. PubMed ID: 35199899
    [No Abstract]   [Full Text] [Related]  

  • 3. Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa.
    Repetto F; Burzi L; Ramondetta A; Rozzo G; Licciardello M; Ribero S; Quaglino P; Dapavo P
    Int J Dermatol; 2022 May; 61(5):e182-e184. PubMed ID: 34270087
    [No Abstract]   [Full Text] [Related]  

  • 4. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
    Tampouratzi E; Kanni T; Katsantonis J; Douvali T
    F1000Res; 2019; 8():2002. PubMed ID: 33456757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P; Akoglu G; Dalkıran CD; Caliskan E
    Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy.
    Wohlmuth-Wieser I; Alhusayen R
    Int J Dermatol; 2021 Apr; 60(4):e140-e141. PubMed ID: 33247833
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.
    Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Arias-Santiago S; Molina-Leyva A
    Dermatol Ther; 2020 May; 33(3):e13456. PubMed ID: 32319172
    [No Abstract]   [Full Text] [Related]  

  • 9. Certolizumab to treat hidradenitis suppurativa.
    Shadid A; Alobaida S; Binamer Y
    Dermatol Reports; 2023 Jun; 15(2):9566. PubMed ID: 37397399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa.
    Tas-Aygar G; Gonul M; Ozcan I; Ayli MD; Ertoy-Baydar D
    Dermatol Ther; 2020 Nov; 33(6):e14205. PubMed ID: 32829493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
    Moul DK; Korman NJ
    Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
    [No Abstract]   [Full Text] [Related]  

  • 12. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?
    Burzi L; Repetto F; Ramondetta A; Rozzo G; Licciardello M; Ribero S; Quaglino P; Dapavo P
    Dermatol Ther; 2021 May; 34(3):e14930. PubMed ID: 33665949
    [No Abstract]   [Full Text] [Related]  

  • 13. Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression.
    Cao Y; Harvey BP; Hong F; Ruzek M; Wang J; Murphy ER; Kaymakcalan Z
    J Invest Dermatol; 2021 Nov; 141(11):2730-2740.e9. PubMed ID: 33965402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hidradenitis suppurativa successfully treated with secukinumab.
    Głowaczewska A; Szepietowski JC; Matusiak Ł
    Dermatol Ther; 2020 Nov; 33(6):e13845. PubMed ID: 32544258
    [No Abstract]   [Full Text] [Related]  

  • 15. Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.
    Megna M; Ruggiero A; Di Guida A; Patrì A; Fabbrocini G; Marasca C
    Dermatol Ther; 2020 Jul; 33(4):e13756. PubMed ID: 32495491
    [No Abstract]   [Full Text] [Related]  

  • 16. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa.
    Frew JW
    Br J Dermatol; 2023 Apr; 188(5):588-589. PubMed ID: 36722365
    [No Abstract]   [Full Text] [Related]  

  • 18. Association and management of Crohn's disease plus hidradenitis suppurativa.
    dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
    Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
    [No Abstract]   [Full Text] [Related]  

  • 19. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab.
    Garcia-Melendo C; Vilarrasa E; Cubiró X; Bittencourt F; Puig L
    Dermatol Ther; 2020 Nov; 33(6):e14180. PubMed ID: 32790040
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report.
    Esme P; Akoglu G; Caliskan E
    Skin Appendage Disord; 2021 Jan; 7(1):58-61. PubMed ID: 33614722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.